Other Events ·
Ainos grants exclusive global rights to VELDONA technology to BioPhoenix for $600K upfront fee plus up to $10M in potential payments
AIMDAinos, Inc.
Ainos, Inc. entered into a Global Exclusive License Agreement with BioPhoenix Co., Ltd. on September 24, 2026, granting worldwide rights to research, develop, and commercialize its VELDONA® low-dose oral interferon alpha technology for Sjögren’s Disease and Thrombocytopenia. BioPhoenix will fund and execute clinical and regulatory activities, reducing Ainos' capital requirements. The agreement includes an upfront license fee of $600,000 payable upon completion of data package delivery and technology transfer. Additional potential fees include a one-time payment for the first sublicense and up to approximately $10 million in total license fees if all additional indications are licensed. Ainos retains 25% of BioPhoenix’s net sublicensing revenue for the Licensed Indications. The company operates in the biotechnology and artificial intelligence sectors, developing chemical sensing technologies and pharmaceutical platforms.